Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells.

@article{Egan2010VitaminDR,
  title={Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate beta-catenin activity in colon cancer cells.},
  author={J. Barry Egan and Patricia A. Thompson and Milen V Vitanov and Leonid Bartik and E. T. A. F. Jacobs and Mark R. Haussler and Eugene W. Gerner and Peter W Jurutka},
  journal={Molecular carcinogenesis},
  year={2010},
  volume={49 4},
  pages={337-52}
}
The activity of beta-catenin, commonly dysregulated in human colon cancers, is inhibited by the vitamin D receptor (VDR), and this mechanism is postulated to explain the putative anti-cancer activity of vitamin D metabolites in the colon. We investigated the effect of a common FokI restriction site polymorphism (F/f) in the human VDR gene as well as the effect of anti-tumorigenic 1,25-dihydroxyvitamin D(3) (1,25D) and pro-tumorigenic lithocholic acid (LCA) VDR ligands on beta-catenin… CONTINUE READING